Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | GSK3B | P49841 | 4/20 | 0.46 |
| ▸ | OGG1 | O15527 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21645315 | 0.94 | CES2 (0.54) | CES2CES1CA1CA2GSK3B | |
| SCHEMBL28646814 | 0.84 | CES2 (0.52) | CES2CES1CA1CA2GSK3B | |
| SCHEMBL2699118 | 0.83 | CES2 (0.46) | CES2CES1CA1CA2GSK3B | |
| SCHEMBL7778212 | 0.82 | CES2 (0.50) | CES2CES1CA1CA2GSK3B | |
| SCHEMBL31191256 | 0.78 | CES2 (0.64) | CES2CES1CA1CA2LMNA | |
| SCHEMBL2096724 | 0.78 | GSK3B (0.64) | CES2CES1CA1CA2GSK3B | |
| SCHEMBL7734235 | 0.78 | CES2 (0.56) | CES2CES1CA1CA2GSK3B | |
| SCHEMBL20135167 | 0.78 | TSHR (0.60) | CES2CES1CA1CA2CA12 | |
| SCHEMBL29003581 | 0.78 | CES2 (0.56) | CES2CES1CA1CA2GSK3B | |
| SCHEMBL557285 | 0.76 | CES2 (1.00) | CES2CES1CA1CA2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729059-A2 | THIAZOLO [5,4-B] PYRIDINE MALT-1 INHIBITORS | Abbvie Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260034140-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LTD (GB) | 2026-02-05 | — | — | US | disclosed |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYSOWAY THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-12453734-B2 | Modulators of rho-associated protein kinase | REDX PHARMA LIMITED (GB) | 2025-10-28 | — | — | US | disclosed |
| CN-119855821-A | Thiazolo [5,4-b ] pyridine MALT-1 inhibitors | 艾伯维公司 | 2025-04-18 | — | — | CN | disclosed |
| EP-4537905-A2 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20250084099-A1 | THIAZOLO[5,4-B]PYRIDINE MALT-1 INHIBITORS | ABBVIE INC (US) | 2025-03-13 | — | — | US | disclosed |
| EP-3774789-B1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2025-03-05 | — | — | EP | disclosed |
| EP-2091937-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | Merck & Co., Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| US-7407959-B2 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA & CO. (CA) | 2008-08-05 | — | — | US | disclosed |
| WO-2008051406-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| EP-1893562-A1 | REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B | Merck Frosst Canada Ltd. (CA) | 2008-03-05 | — | — | EP | disclosed |
| US-20070293578-A1 | Cathepsin Cysteine Protease Inhibitors | GAUTHIER JACQUES Y | 2007-12-20 | — | — | US | disclosed |
| EP-1817276-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006056047-A9 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2007-06-21 | — | — | WO | disclosed |
| WO-2006133559-A1 | REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B | MERCK FROSST CANADA LTD. (CA) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006056047-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2006-06-01 | — | — | WO | disclosed |
| US-20060111440-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034140-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK1, ROCK2, RHOA | CES2 4176/4885CES1 3261/4885CA1 3571/4885 |
| US-12453734-B2 | Modulators of rho-associated protein kinase | ROCK2, ROCK1, RHOA | CES2 4324/4885CES1 2245/4885CA1 4161/4885 |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ADRM1, SUMO2, BAZ1A | CES2 2798/4885CES1 2876/4885CA1 4427/4885 |
| US-20060111440-A1 | Cathepsin cysteine protease inhibitors | CTSB, CTSS, CTSZ | CES2 1473/4885CES1 250/4885CA1 1159/4885 |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, VHL, BAZ1A | CES2 2677/4885CES1 2371/4885CA1 4190/4885 |
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | STOML2, ATP2A3, ATP2A1 | CES2 1765/4885CES1 1397/4885CA1 2863/4885 |
| US-20070293578-A1 | Cathepsin Cysteine Protease Inhibitors | CTSB, CTSS, CTSE | CES2 1371/4885CES1 292/4885CA1 1146/4885 |
| US-20250084099-A1 | THIAZOLO[5,4-B]PYRIDINE MALT-1 INHIBITORS | MALT1, PTP4A1, AMY1A | CES2 3580/4885CES1 1082/4885CA1 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.